ClinicalTrials.gg
CompletedNCT01266369Updated Dec 10, 2018

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

A Phase 2 interventional study of masitinib in Mastocytosis, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-10.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of patients with mastocytosis with handicap and bearing activating point mutations in the phosphotransferase domain of c-Kit such as the main mutation Asp-816-Val (D816V).

02

Conditions studied

  • Mastocytosis

Browse trials for

Keywords

  • mastocytosis
  • D816V
  • handicaps
03

In context

Mastocytosis

49 studies on the registry are indexed under Mastocytosis; 14 are open to participants now.

This study's enrollment of 21 is below the median of 30 across 23 interventional studies indexed under Mastocytosis.

Browse Mastocytosis studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with one of the following documented mastocytosis:

    • Smouldering systemic mastocytosis
    • Indolent systemic mastocytosis with organomegaly
    • Indolent Systemic Mastocytosis having 2 infiltrated organs (skin and bone-marrow)
    • Any mastocytosis with in the last 6 months at least 3 anaphylactic shocks or syncops requiring either use of adrenaline or medical assistance
    • Cutaneous Mastocytosis (CM)
  2. Skin -documented mastocytosis and evaluable disease based upon:

    • Histological criteria: typical infiltrates of mast cells in a multifocal or diffuse pattern in skin biopsy
    • Clinical criteria: typical skin lesions (maculopapular, urticaria pigmentosa, mastocytoma)
  3. Missing data (c-kit molecular analysis not done) or documented presence of an activating point mutation in the phosphotransferase domain of c-kit such as D816V c-kit mutation in at least one infiltrated organ (bone marrow or skin)
  4. to at least one of the symptomatic treatments such as:

    • Anti H1
    • Anti H2
    • Proton pump inhibitor
    • Osteoclast inhibitor
    • Cromoglycate Sodium
    • Antileukotriene
    • Other therapies used for the symptomatic care
  5. Handicap defined as at least one of the following handicaps:

    • pruritus score ≥ 6
    • number of flushes per week ≥ 7
    • number of stools per day ≥ 4 ,
    • number of mictions per day ≥ 8 ,
    • QLQ-C30 score ≥ 60,
    • Hamilton score ≥ 10

Exclusion criteria

Exclusion Criteria:

  1. Patients with one of the following mastocytosis:

    • Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD)
    • Mast cell leukemia (MCL)
    • Aggressive systemic mastocytosis (ASM)
  2. Patient with a major surgery within 2 weeks prior to study entry
  3. No vulnerable population will be included in this study

    • \< 6 months.
    • Patient is \< 5 years free of , except treated basal cell skin cancer or cervical carcinoma in situ.
    • Patient with grade III/IV cardiac problems as defined by the Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
    • Patient has a severe and/or uncontrolled medical disease.
    • Patient has a known diagnosis of (HIV) infection
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    masitinib 3 mg/kg/day

    masitinib 3 mg/kg/day

    Drug: masitinib

  • Experimental
    masitinib 6 mg/kg/day

    masitinib 6 mg/kg/day

    Drug: masitinib

Interventions

06

What researchers measure

Primary outcomes

  1. efficacy on handicaps

    Pruritus score at week 12 Number of flushes per week at week 12 Hamilton score at week 12 Fatigue Impact scale at week 12

    Time frame: week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Nov 2007 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2010
First posted
Dec 24, 2010
Start
Feb 2007
Primary completionActual
Nov 2007
CompletionActual
May 2010
Last update
Dec 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01266369
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 24, 2010
Start date
Feb 2007
Primary completion
Nov 2007
Completion
May 2010
Last update
Dec 10, 2018

Study contacts

Olivier Lortholary, MD, PhD
principal investigator · Necker Hospital, Paris, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion